NeurAxis, Inc. entered into a securities purchase agreement for issuance of 1,260,504 series B convertible preferred stock at price of $2.38 per share for gross proceeds of $3,000,000 on November 9, 2023. The transaction will include participation from new investor Flagstaff International, Inc. The aggregate purchase price is to be paid in 15 monthly installments of $200,000 each, commencing on the later of January 10, 2024 or a date after stockholders approve of an amendment to the company?s certificate of incorporation to authorize the creation of the shares. The series B preferred stock is convertible at any time into shares of common stock of the company without any further consideration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.97 USD | -1.00% | -0.67% | +11.24% |
07/06 | NeurAxis Submits Application to FDA to Expand IB-Stim Label | MT |
22/05 | Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635 | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.24% | 1.97Cr | |
+75.69% | 1.26TCr | |
-25.35% | 727.93Cr | |
+15.77% | 720.32Cr | |
+14.52% | 546.87Cr | |
-18.50% | 472.6Cr | |
+14.91% | 409.48Cr | |
-23.67% | 377.97Cr | |
-30.22% | 263.37Cr | |
+42.93% | 229.64Cr |
- Stock Market
- Equities
- NRXS Stock
- News NeurAxis, Inc.
- NeurAxis, Inc. announced that it expects to receive $3 million in funding from Flagstaff International, Inc